These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8911111)

  • 1. Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group.
    McLeod HL; Graham MA; Aamdal S; Setanoians A; Groot Y; Lund B
    Eur J Cancer; 1996 Aug; 32A(9):1518-22. PubMed ID: 8911111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group.
    Verweij J; Aamdal S; Schellens J; Koier I; Lund B
    Oncol Res; 1994; 6(10-11):519-23. PubMed ID: 7620220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9.
    Schellens JH; Dombernowsky P; Cassidy J; Epelbaum R; Dirix L; Cox EH; Wanders J; Calabresi F; Paridaens R; Monfardini S; Wolff J; Loos WJ; Verweij J; Pavlidis N; Hanauske AR;
    Anticancer Drugs; 2001 Aug; 12(7):583-90. PubMed ID: 11487714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents.
    Workman P; Binger M; Kooistra KL
    Int J Radiat Oncol Biol Phys; 1992; 22(4):713-6. PubMed ID: 1544843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.
    Schellens JH; Planting AS; van Acker BA; Loos WJ; de Boer-Dennert M; van der Burg ME; Koier I; Krediet RT; Stoter G; Verweij J
    J Natl Cancer Inst; 1994 Jun; 86(12):906-12. PubMed ID: 8196081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG).
    Aamdal S; Lund B; Koier I; Houten M; Wanders J; Verweij J
    Cancer Chemother Pharmacol; 2000; 45(1):85-8. PubMed ID: 10647507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.
    Hendriks HR; Pizao PE; Berger DP; Kooistra KL; Bibby MC; Boven E; Dreef-van der Meulen HC; Henrar RE; Fiebig HH; Double JA
    Eur J Cancer; 1993; 29A(6):897-906. PubMed ID: 8484984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group.
    Dirix LY; Tonnesen F; Cassidy J; Epelbaum R; ten Bokkel Huinink WW; Pavlidis N; Sorio R; Gamucci T; Wolff I; Te Velde A; Lan J; Verweij J
    Eur J Cancer; 1996 Oct; 32A(11):2019-22. PubMed ID: 8943690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of EO9 anti-tumour activity by hydralazine.
    Bibby MC; Sleigh NR; Loadman PM; Double JA
    Eur J Cancer; 1993; 29A(7):1033-5. PubMed ID: 8499134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice.
    Loadman PM; Phillips RM; Lim LE; Bibby MC
    Biochem Pharmacol; 2000 Apr; 59(7):831-7. PubMed ID: 10718341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioreductive agents: a clinical update.
    Boyer MJ
    Oncol Res; 1997; 9(6-7):391-5. PubMed ID: 9406245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9.
    Choudry GA; Stewart PA; Double JA; Krul MR; Naylor B; Flannigan GM; Shah TK; Brown JE; Phillips RM
    Br J Cancer; 2001 Oct; 85(8):1137-46. PubMed ID: 11710826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG).
    Pavlidis N; Hanauske AR; Gamucci T; Smyth J; Lehnert M; te Velde A; Lan J; Verweij J
    Ann Oncol; 1996 Jul; 7(5):529-31. PubMed ID: 8839911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines.
    Plumb JA; Gerritsen M; Milroy R; Thomson P; Workman P
    Int J Radiat Oncol Biol Phys; 1994 May; 29(2):295-9. PubMed ID: 8195022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological and biochemical determinants of the antitumour activity of the indoloquinone EO9.
    Cummings J; Spanswick VJ; Gardiner J; Ritchie A; Smyth JF
    Biochem Pharmacol; 1998 Feb; 55(3):253-60. PubMed ID: 9484790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity.
    Plumb JA; Workman P
    Int J Cancer; 1994 Jan; 56(1):134-9. PubMed ID: 8262670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9.
    Loadman PM; Bibby MC; Phillips RM
    Br J Pharmacol; 2002 Nov; 137(5):701-9. PubMed ID: 12381684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9.
    Smitskamp-Wilms E; Hendriks HR; Peters GJ
    Gen Pharmacol; 1996 Apr; 27(3):421-9. PubMed ID: 8723519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours.
    Phillips RM; Loadman PM; Cronin BP
    Br J Cancer; 1998 Jun; 77(12):2112-9. PubMed ID: 9649122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The experimental development of bioreductive drugs and their role in cancer therapy.
    Workman P; Stratford IJ
    Cancer Metastasis Rev; 1993 Jun; 12(2):73-82. PubMed ID: 8375022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.